

Corrected Revenue Tables:

On the schedule titled “REVENUE BY OPERATING SEGMENT – INTERNATIONAL” we have revised the revenue for all periods for our Revascularization & Surgical Therapies and Structural Heart Disease businesses. The revision did not impact total Worldwide or US revenue for either of these businesses.

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT - WORLD WIDE
(Unaudited)

(\$ millions)

	FY 07 QTR 1	FY 07 QTR 2	FY 07 QTR 3	FY 07 QTR 4	FY 07 Total	FY 08 QTR 1	FY 08 QTR 2	FY 08 QTR 3	FY 08 QTR 4	FY 08 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 1,149	\$ 1,252	\$ 1,186	\$ 1,291	\$ 4,876	\$ 1,235	\$ -	\$ -	\$ -	\$ 1,235
Pacing Systems	460	473	458	504	1,895	494	-	-	-	494
Defibrillation Systems	673	764	711	770	2,917	726	-	-	-	726
Other	16	15	17	17	64	15	-	-	-	15
SPINAL	\$ 575	\$ 599	\$ 598	\$ 643	\$ 2,417	\$ 644	\$ -	\$ -	\$ -	\$ 644
Spinal Instrumentation	412	421	429	456	1,721	454	-	-	-	454
Spinal Biologics	163	178	169	187	696	190	-	-	-	190
CARDIOVASCULAR	\$ 448	\$ 455	\$ 478	\$ 528	\$ 1,909	\$ 486	\$ -	\$ -	\$ -	\$ 486
Coronary Stents	120	132	148	161	560	152	-	-	-	152
Other Coronary/Peripheral	99	92	92	100	386	95	-	-	-	95
Endovascular	61	63	64	72	259	69	-	-	-	69
Revasc & Surgical Therapies	100	98	105	114	417	102	-	-	-	102
Structural Heart Disease	68	70	69	81	287	68	-	-	-	68
NEUROMODULATION	\$ 276	\$ 291	\$ 290	\$ 326	\$ 1,183	\$ 289	\$ -	\$ -	\$ -	\$ 289
Neuro Implantables	226	238	233	265	962	237	-	-	-	237
Gastroenterology & Urology	50	53	57	61	221	52	-	-	-	52
DIABETES	\$ 196	\$ 212	\$ 226	\$ 229	\$ 863	\$ 241	\$ -	\$ -	\$ -	\$ 241
EAR, NOSE & THROAT (ENT)	\$ 128	\$ 129	\$ 134	\$ 147	\$ 539	\$ 144	\$ -	\$ -	\$ -	\$ 144
Core ENT	65	65	69	77	278	75	-	-	-	75
Neurologic Technologies	63	64	65	70	261	69	-	-	-	69
CORPORATE TECHNOLOGIES AND NEW VENTURES	\$ 24	\$ 26	\$ 31	\$ 47	\$ 127	\$ 28	\$ -	\$ -	\$ -	\$ 28
PHYSIO-CONTROL	\$ 101	\$ 111	\$ 105	\$ 69	\$ 385	\$ 60	\$ -	\$ -	\$ -	\$ 60
TOTAL	\$ 2,897	\$ 3,075	\$ 3,048	\$ 3,280	\$ 12,299	\$ 3,127	\$ -	\$ -	\$ -	\$ 3,127
ADJUSTMENTS :										
CURRENCY (1)	\$ 6	\$ 32	\$ 55	\$ 71	\$ 166	\$ 49				\$ 49
COMPARABLE OPERATIONS (1)	\$ 2,891	\$ 3,043	\$ 2,993	\$ 3,209	\$ 12,133	\$ 3,078	\$ -	\$ -	\$ -	\$ 3,078

(1) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT - US
(Unaudited)

(\$ millions)

	FY 07 QTR 1	FY 07 QTR 2	FY 07 QTR 3	FY 07 QTR 4	FY 07 Total	FY 08 QTR 1	FY 08 QTR 2	FY 08 QTR 3	FY 08 QTR 4	FY 08 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 733	\$ 807	\$ 737	\$ 773	\$ 3,048	\$ 754	\$ -	\$ -	\$ -	\$ 754
Pacing Systems	228	244	220	240	931	244	-	-	-	244
Defibrillation Systems	495	554	507	525	2,082	504	-	-	-	504
Other	10	9	10	8	35	6	-	-	-	6
SPINAL	\$ 480	\$ 505	\$ 502	\$ 531	\$ 2,019	\$ 530	\$ -	\$ -	\$ -	\$ 530
Spinal Instrumentation	322	333	338	353	1,348	349	-	-	-	349
Spinal Biologics	158	172	164	178	671	181	-	-	-	181
CARDIOVASCULAR	\$ 170	\$ 174	\$ 173	\$ 189	\$ 707	\$ 167	\$ -	\$ -	\$ -	\$ 167
Coronary Stents	9	12	17	22	61	20	-	-	-	20
Other Coronary/Peripheral	37	36	29	30	130	24	-	-	-	24
Endovascular	33	35	34	37	140	35	-	-	-	35
Revasc & Surgical Therapies	52	51	53	56	213	49	-	-	-	49
Structural Heart Disease	39	40	40	44	163	39	-	-	-	39
NEUROMODULATION	\$ 196	\$ 215	\$ 207	\$ 226	\$ 844	\$ 201	\$ -	\$ -	\$ -	\$ 201
Neuro Implantables	157	173	164	180	674	160	-	-	-	160
Gastroenterology & Urology	39	42	43	46	170	41	-	-	-	41
DIABETES	\$ 140	\$ 154	\$ 164	\$ 158	\$ 616	\$ 163	\$ -	\$ -	\$ -	\$ 163
EAR, NOSE & THROAT (ENT)	\$ 87	\$ 88	\$ 91	\$ 96	\$ 362	\$ 93	\$ -	\$ -	\$ -	\$ 93
Core ENT	43	44	47	49	183	48	-	-	-	48
Neurologic Technologies	44	44	44	47	179	45	-	-	-	45
CORPORATE TECHNOLOGIES AND NEW VENTURES	\$ 17	\$ 17	\$ 21	\$ 30	\$ 85	\$ 19	\$ -	\$ -	\$ -	\$ 19
PHYSIO-CONTROL	\$ 60	\$ 73	\$ 62	\$ 24	\$ 219	\$ 21	\$ -	\$ -	\$ -	\$ 21
TOTAL	\$ 1,883	\$ 2,033	\$ 1,957	\$ 2,027	\$ 7,900	\$ 1,948	\$ -	\$ -	\$ -	\$ 1,948
ADJUSTMENTS :										
CURRENCY	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
COMPARABLE OPERATIONS	\$ 1,883	\$ 2,033	\$ 1,957	\$ 2,027	\$ 7,900	\$ 1,948	\$ -	\$ -	\$ -	\$ 1,948

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenue.

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT - INTERNATIONAL
(Unaudited)

(\$ millions)

	FY 07 QTR 1	FY 07 QTR 2	FY 07 QTR 3	FY 07 QTR 4	FY 07 Total	FY 08 QTR 1	FY 08 QTR 2	FY 08 QTR 3	FY 08 QTR 4	FY 08 Total
REPORTED REVENUE :										
CARDIAC RHYTHM DISEASE MANAGEMENT	\$ 416	\$ 445	\$ 449	\$ 518	\$ 1,828	\$ 481	\$ -	\$ -	\$ -	\$ 481
Pacing Systems	232	229	238	264	964	250	-	-	-	250
Defibrillation Systems	178	210	204	245	835	222	-	-	-	222
Other	6	6	7	9	29	9	-	-	-	9
SPINAL	\$ 95	\$ 94	\$ 96	\$ 112	\$ 398	\$ 114	\$ -	\$ -	\$ -	\$ 114
Spinal Instrumentation	90	88	91	103	373	105	-	-	-	105
Spinal Biologics	5	6	5	9	25	9	-	-	-	9
CARDIOVASCULAR	\$ 278	\$ 281	\$ 305	\$ 339	\$ 1,202	\$ 319	\$ -	\$ -	\$ -	\$ 319
Coronary Stents	111	120	131	139	499	132	-	-	-	132
Other Coronary/Peripheral	62	56	63	70	256	71	-	-	-	71
Endovascular	28	28	30	35	119	34	-	-	-	34
Revasc & Surgical Therapies	48	47	52	58	204	53	-	-	-	53
Structural Heart Disease	29	30	29	37	124	29	-	-	-	29
NEUROMODULATION	\$ 80	\$ 76	\$ 83	\$ 100	\$ 339	\$ 88	\$ -	\$ -	\$ -	\$ 88
Neuro Implantables	69	65	69	85	288	77	-	-	-	77
Gastroenterology & Urology	11	11	14	15	51	11	-	-	-	11
DIABETES	\$ 56	\$ 58	\$ 62	\$ 71	\$ 247	\$ 78	\$ -	\$ -	\$ -	\$ 78
EAR, NOSE & THROAT (ENT)	\$ 41	\$ 41	\$ 43	\$ 51	\$ 177	\$ 51	\$ -	\$ -	\$ -	\$ 51
Core ENT	22	21	22	28	95	27	-	-	-	27
Neurologic Technologies	19	20	21	23	82	24	-	-	-	24
CORPORATE TECHNOLOGIES AND NEW VENTURES	\$ 7	\$ 9	\$ 10	\$ 17	\$ 42	\$ 9	\$ -	\$ -	\$ -	\$ 9
PHYSIO-CONTROL	\$ 41	\$ 38	\$ 43	\$ 45	\$ 166	\$ 39	\$ -	\$ -	\$ -	\$ 39
TOTAL	\$ 1,014	\$ 1,042	\$ 1,091	\$ 1,253	\$ 4,399	\$ 1,179	\$ -	\$ -	\$ -	\$ 1,179
ADJUSTMENTS :										
CURRENCY (1)	\$ 6	\$ 32	\$ 55	\$ 71	\$ 166	\$ 49	\$ -	\$ -	\$ -	\$ 49
COMPARABLE OPERATIONS (1)	\$ 1,008	\$ 1,010	\$ 1,036	\$ 1,182	\$ 4,233	\$ 1,130	\$ -	\$ -	\$ -	\$ 1,130

(1) Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.